OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis $52.25 0.00 (0.00%) (As of 08/1/2024) Add Compare Share Share Today's Range$52.25▼$52.2550-Day Range$51.60▼$52.2552-Week Range$52.25▼$52.25Volume500 shsAverage VolumeN/AMarket CapitalizationN/AP/E Ratio18.80Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Recordati Industria Chimica e Farmaceutica alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF)Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More RCDTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCDTF Stock News HeadlinesAugust 26, 2024 | markets.businessinsider.comJefferies Remains a Hold on Recordati Industria Chimica e Farmaceutica SPA (0KBS)July 31, 2024 | seekingalpha.comRecordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Q1 2024 Earnings Call TranscriptSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 30, 2024 | msn.comItaly's Recordati hikes 2024 guidance after core profit rises 11.5%July 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from Recordati Industria Chimica e Farmaceutica SPAAz Post raggruppamento's earnings reportJuly 20, 2024 | markets.businessinsider.comKepler Capital Sticks to Their Hold Rating for Recordati Industria Chimica e Farmaceutica SPA (0KBS)May 8, 2024 | markets.businessinsider.comHere's what to expect from Recordati Industria Chimica e Farmaceutica SPAAz Post raggruppamento's earningsApril 24, 2024 | msn.comBorsa: Milano fiacca con Recordati e Saipem, vola StmSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 23, 2024 | msn.comCVC explores options for Italy's Recordati, Bloomberg News reportsApril 23, 2024 | finance.yahoo.comCVC Explores Options for €11 Billion Drugmaker RecordatiApril 23, 2024 | finance.yahoo.comUPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reportsMarch 19, 2024 | msn.comFarmaceutica, le big si muovono: Astrazeneca acquista, Pfizer vende. Da Recordati cedola maggiorata con un occhio alle opportunitàDecember 29, 2023 | msn.comBorsa Milano, lieve rialzo (+0,07%), Recordati e banche in rialzoDecember 19, 2023 | seekingalpha.comRICFY Recordati Industria Chimica e Farmaceutica S.p.A.November 7, 2023 | msn.comItaly's Recordati sees 2023 results at top end of the rangeNovember 7, 2023 | uk.news.yahoo.comItaly's Recordati nudges up 2023 guidance as 9-mth revenue, profit jumpsSeptember 9, 2023 | forbes.comFondo pensione: cos’è e come funzionaSee More Headlines Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CUSIPN/A CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,455Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio18.80 Forward P/E Ratio17.89 P/E GrowthN/ANet Income$421.25 million Net Margins17.41% Pretax Margin23.58% Return on Equity30.78% Return on Assets12.65% Debt Debt-to-Equity Ratio0.73 Current Ratio1.36 Quick Ratio0.95 Sales & Book Value Annual Sales$2.25 billion Price / SalesN/A Cash Flow$3.06 per share Price / Cash Flow17.08 Book Value$7.90 per share Price / Book6.61Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.33 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Robert Koremans M.D. (Age 62)CEO & Director Comp: $1.94MMr. Luigi Felice La Corte (Age 55)Group CFO & Executive Director Comp: $1.02MMs. Cathrin Petty (Age 51)Executive Director Mr. Giampiero Mazza (Age 55)Executive Director Mr. Giorgio De Palma (Age 50)Executive Director Ms. Eugenia LitzVP & Head of Investor RelationsMs. Bibianne BonGroup Chief Legal OfficerMs. Laura ContiGroup Communications DirectorMr. Gabriele FinziExecutive VP of Corporate Development, Licensing & InnovationMs. Alessandra AbateGroup Chief People & Culture OfficerMore ExecutivesKey CompetitorsAllkemOTCMKTS:OROCFAmplifonOTCMKTS:AMFPFAndritzOTCMKTS:ADRZYAssa AbloyOTC:ASAZYBayerische Motoren Werke AktiengesellschaftOTCMKTS:BAMXFView All Competitors RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 at the beginning of 2024. Since then, RCDTF shares have increased by 13.6% and is now trading at $52.25. View the best growth stocks for 2024 here. How were Recordati Industria Chimica e Farmaceutica's earnings last quarter? Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) released its quarterly earnings data on Tuesday, July, 30th. The company reported $0.70 EPS for the quarter. The firm had revenue of $622 million for the quarter. Recordati Industria Chimica e Farmaceutica had a trailing twelve-month return on equity of 30.78% and a net margin of 17.41%. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RCDTF) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)The Dow recently shed nearly 1,000 points in a single day… Big tech stocks are getting slaughtered… And ...Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica e Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RCDTF Stock Alerts